Why the study?
The efficacy and safety of cerebral embolic protection devices in stroke prevention during transcatheter aortic valve replacement remained uncertain.
Does the use of cerebral embolic protection devices (CEPD) reduce the incidence of stroke in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR)?
Does the use of cerebral embolic protection devices (CEPD) reduce the incidence of stroke in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR)?
Answers are grounded in this paper and cite their sources.
In this updated meta-analysis of 8 RCTs including the large BHF PROTECT-TAVI trial (n=11,596), cerebral embolic protection devices during TAVR did not significantly reduce the risk of any stroke, disabling stroke, or all-cause mortality.
Cerebral embolic protection devices (CEPD) have been designed to prevent embolization to the cerebral circulation during transcatheter aortic valve replacement (TAVR). However, the efficacy and safety of CEPD in stroke prevention in TAVR remains uncertain. PubMed, Embase, and Cochrane Library were searched for randomized controlled trials (RCTs) comparing CEPD vs. control for patients undergoing TAVR. Risk ratios (RR) with 95% confidence intervals (CI) were pooled with a random-effects model. Our meta-analysis included eight RCTs with 11,596 patients, of whom 5,946 (51%) were randomized to the CEPD group. There was no significant difference in the incidence of any stroke (3.51% vs. 3.64%; RR 0.91; 95% CI 0.75-1.1; p=0.33; I 2 =0%) between groups. Similarly, CEPD did not significantly reduce the incidence of all-cause mortality (0.82% vs. 0.67%; RR 1.13; 95% CI 0.74-1.74; p=0.57; I 2 =0%) Among patients undergoing TAVR, CEPD did not significantly reduce stroke incidence or all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Mansouri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: